A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumors.

Auteurs : Schöffski P, Aftimos P, Dumez H, Deleporte A, De Block K, Costermans J, Billiet M, Meeus MA, Lee C, Schnell D, Goeldner RG, Awada A
Année : 2016
Journal : Cancer Chemother Pharmacol
Volume : 77(1)
Pages : 99-108

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR Trial.

Auteurs : Gebhart G, Lamberts LE, Wimana Z, Garcia C, Emonts P, Ameye L, Stroobants S, Huizing M, Aftimos P, Tol J, Oyen WJ, Vugts DJ, Hoekstra OS, Schröder CP, Menke-van der Houven van Oordt CW, Guiot T, Brouwers AH, Awada A, de Vries EG, Flamen P
Année : 2016
Journal : Ann Oncol
Volume : 27(4)
Pages : 619-24

'New' metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy, Breast Cancer Research 2015, 17: 150

Auteurs : Twelves C, Cortes J, Kaufman PA, Yelle L, Awada A, Binder T, Olivo M, O Shaughnessy J, Jove M, Perez EA
Année : 2015
Journal : Breast Cancer Res
Volume : 17
Pages : 150

Thrombo-embolic events in cancer patients with impaired renal function

Auteurs : Elalamy I, Canon JL, Bols A, Lybaert W, Duck L, Jochmans K, Bosquée L, Peeters M, Awada A, Clement P, Holbrechts S, Baurain JF, Mebis J, Nortier J
Année : 2015
Journal : Belgian J Medical Oncology
Volume : 9(2)
Pages : 53-60

Utility of Next-Generation Sequencing in Cancer Drug Development and Clinical Trials, Next Generation Sequencing in Cancer Research 2015,

Auteurs : Thomas F, Awada A
Année : 2015
Journal : Book
Volume : 2
Pages : 19-37

Epidemiological risk factors for breast cancer in premenopausal women, Maternal Medicine 2015 (ebook; McGraw-Hill Education / Medical; 1 edition (22 July 2015))

Auteurs : Pinto AC, Azim HA, Lambertini M, Awada A, Ibrahim NK
Année : 2015
Journal : Book
Volume : -
Pages : -

Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial.

Auteurs : Cortes J, Hudgens S, Twelves C, Perez EA, Awada A, Yelle L, McCutcheon S, Kaufman PA, Forsythe A, Velikova G
Année : 2015
Journal : Breast Cancer Res Treat
Volume : 154
Pages : 509-20

Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial.

Auteurs : Perez EA, Awada A, OShaughnessy J, Rugo HS, Twelves C, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, Cortes J
Année : 2015
Journal : Lancet Oncol
Volume : 16
Pages : 1556-68

Novel mechanisms and approaches in the medical therapy of solid cancers.

Auteurs : Awada G, Kourie HR, Awada A
Année : 2015
Journal : Discov Med
Volume : 20
Pages : 33-41

Will modern immunotherapies become the standard of care for advanced synchronous or metachronous cancers?

Auteurs : Kourie HR, Awada A
Année : 2015
Journal : Future Oncol
Volume : 11
Pages : 3053-5

SNPs at miR-155 binding sites of TYRP1 explain discrepancy between mRNA and protein and refine TYRP1 prognostic value in melanoma.

Auteurs : El Hajj P, Gilot D, Migault M, Theunis A, Van Kempen LC, Sales F, Fayyad-Kazan H, Badran B, Larsimont D, Awada A, Bachelot L, Galibert MD, Ghanem G, Journe F
Année : 2015
Journal : Br J Cancer
Volume : 113(1)
Pages : 91-8

A first-in-human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours.

Auteurs : Venugopal B, Awada A, Evans TR, Dueland S, Hendlisz A, Rasch W, Hernes K, Hagen S, Aamdal S
Année : 2015
Journal : Cancer Chemother Pharmacol
Volume : 76(4)
Pages : 785-92

Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity.

Auteurs : Awada A, Dumez H, Aftimos P, Costermans J, Bartholomeus S, Forceville K, Berghmans T, Meeus MA, Cescutti J, Munzert G, Pilz K, Liu D, Schöffski P
Année : 2015
Journal : Invest New Drugs
Volume : 33(3)
Pages : 611-20

Erratum: Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study.

Auteurs : Hendlisz A, Golfinopoulos V, Deleporte A, Paesmans M, El Mansy H, Garcia C, Peeters M, Annemans L, Vandeputte C, Maetens M, Van den Eynde M, Maréchal R, Borbath I, Dresse D, Houbiers G, Fried M, Awada A, Piccart-Gebhart M, Van Laethem JL, Flamen P
Année : 2015
Journal : BMC Cancer
Volume : 15
Pages : 173

Erratum to: Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies.

Auteurs : Twelves C, Cortes J, Vahdat L, Olivo M, He Y, Kaufman PA, Awada A
Année : 2015
Journal : Breast Cancer Res. Treat.
Volume : 149(1)
Pages : 313

Evaluating the pharmacokinetics and pharmacodynamics of everolimus for treating breast cancer.

Auteurs : Gombos A, Barthélémy P, Awada A
Année : 2015
Journal : Expert Opin Drug Metab Toxicol
Volume : 11(5)
Pages : 823-34.

New generations of targeted therapies fighting the resistance in solid tumors.

Auteurs : Barthélémy P, Aftimos P, Awada A
Année : 2015
Journal : Curr Opin Oncol
Volume : 27(3)
Pages : 243-9

Metabolic disorders associated with the use of targeted cancer therapies.

Auteurs : Kotecki N, Penel N, Awada A
Année : 2015
Journal : Curr Opin Oncol
Volume : 27(3)
Pages : 258-66

Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane.

Auteurs : Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, Olivo MS, He Y, Dutcus CE, Cortes J
Année : 2015
Journal : J. Clin. Oncol.
Volume : 33(6)
Pages : 594-601

Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer.

Auteurs : Rothé F, Laes JF, Lambrechts D, Smeets D, Vincent D, Maetens M, Fumagalli D, Michiels S, Drisis S, Moerman C, Detiffe JP, Larsimont D, Awada A, Piccart-Gebhart M, Sotiriou C, Ignatiadis M
Année : 2014
Journal : Ann Oncol
Volume : 25(10)
Pages : 1959-65